PT-141
FDA ApprovedAlso known as: Bremelanotide, PT141
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist studied for its role in sexual arousal pathways. It is the first peptide approved specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Sexual Function
Acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R), activating central nervous system pathways involved in sexual arousal, independent of the vascular mechanisms targeted by PDE5 inhibitors.
FDA-approved (Vyleesi) for HSDD in premenopausal women. Common side effects include nausea, flushing, headache, and transient blood pressure elevation. Not for use in cardiovascular disease.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA et al. (2019). Obstetrics & Gynecology.DOI: 10.1097/AOG.0000000000003500
Want to learn more?
Ask Research Chat about PT-141Half-Life
~2.7 hours
Administration
subcutaneous injection (approved), nasal spray (discontinued)
Legal Status (US)
FDA-approved prescription medication (Vyleesi).
217 indexed research passages
Related Peptides
Oxytocin is a nine-amino acid neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary, studied extensively for its roles in social bonding, trust, maternal behavior, uterine contraction, and lactation. It is FDA-approved for obstetric indications and has been extensively studied in clinical contexts including autism spectrum disorder and social anxiety.
Mirodenafil is a PDE5 inhibitor developed in South Korea and approved there for the management of erectile dysfunction. Research has examined its pharmacological profile relative to other PDE5 inhibitors, with studies suggesting a rapid onset of action. It is not approved by the FDA.
Androstadienone is an endogenous androgen derivative found in male sweat and axillary secretions, studied as a potential human chemosignal with effects on mood, social cognition, and neuroendocrine responses in females. Research has examined its ability to influence cortisol levels, attention to emotional stimuli, and social evaluation processes.
Tadalafil is an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor used clinically for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is distinguished among PDE5 inhibitors by its long duration of action, with effects studied for up to 36 hours.